目的 比较奈达铂联合紫杉醇与伊立替康联合紫杉醇作为首选方案治疗中晚期宫颈癌的疗效.方法 对90例中晚期宫颈癌患者采用不同的化疗方案进行治疗,其中对照组患者采用奈达铂联合紫杉醇,观察组采用伊立替康联合紫杉醇.对2组患者的近期疗效、远期疗效、不良反应以及远期生存率进行对比观察.结果 观察组患者有效率为75.56%,显著高于对照组的51.11%(P＜0.05).观察组患者1年、3年生存率分别为71.11%、55.56%,高于对照组的55.56%、31.11%(P＜0.05).此外,2组患者均出现不同程度的不良反应,其中消化道不适方面,观察组患者明显少于对照组(P＜0.05).结论 伊立替康联合紫杉醇治疗中晚期宫颈癌具有较高的有效率,不良反应较少,并能明显提高患者的远期生存率,值得临床推广.%Objective To compare the efficacy of nedaplatin or irinotecan combined with paclitaxel as first choice for interim or advanced cervical cancer. Methods 90 patients with interim or advanced cervical cancer received different chemothera -py regimens for treatment. The control group were treated with nedaplatin combined with paclitaxel , the observation group were treated with irinotecan and paclitaxel. Short-term efficacy , long-term efficacy, adverse reactions and long-term survival rates were compared. Results Effective rate of the observation group was 75. 56% , significantly higher than 51. 11% in the control group (P <0. 05). The 1-year,3-year survival rates were 71. 11% ,55. 56% in the observation group ,higher than 55. 56% ,31. 11% in the control group , (P < 0. 05 ). In addition, the 2 groups had adverse reactions in varied degrees . Gastrointestinal discomfort of the observation group were significantly less than that of the control group (P < 0. 05). Conclusion Irinotecan combined with pacli -taxel is an effective treatment for interim or advanced cervical cancer with fewer adverse reactions , and can significantly improve long-term survival rates of patients . It is worthy of further clinical application .
展开▼
